Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B7 homolog 3 protein (B7-H3), also known as CD276, is a member of the B7 family of immune regulatory proteins. It functions primarily as an immune checkpoint molecule and plays complex roles in modulating immune responses, particularly within the tumor microenvironment. It acts as both a costimulatory and coinhibitory molecule, promoting tumor cell migration, invasion, angiogenesis, chemoresistance, and epithelial-to-mesenchymal transition. B7-H3 is overexpressed in many solid tumors and correlates with poor prognosis, making it a promising target for immunotherapy.
Monoclonal antibodies targeting B7-H3; Antibody-drug conjugates targeting B7-H3; CAR-T cell therapies targeting B7-H3-expressing tumors
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B7 Homolog 3 Protein (B7-H3).